Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
In treatment trials for Major Depressive Disorder (MDD), early symptom improvement is predictive of eventual clinical response. Clinical response may also be predicted by elevated pretreatment theta (4-7 Hz) current density in the rostral anterior cingulate (rACC) and medial orbitofrontal cortex (mOFC). We investigated the relationship between pretreatment EEG and early improvement in predicting clinical outcome in 72 MDD subjects across three placebo-controlled treatment trials. Subjects were randomized to receive fluoxetine, venlafaxine, or placebo. Theta current density in the rACC and mOFC was computed with Low-Resolution Brain Electromagnetic Tomography (LORETA). An ANCOVA, examining week 8 Hamilton Depression Rating Scale (HamD) percent change, showed a significant effect of week-2-HamD-percent-change, and a significant three-way interaction of week-2-HamD-percent-change × Treatment × rACC. Medication subjects with robust early improvement showed almost no relationship between rACC theta current density and final clinical outcome. However, in subjects with little early improvement, rACC activity showed a strong relationship with clinical outcome. The model examining mOFC showed a trend in the three-way interaction. A combination of pretreatment rACC activity and early symptom improvement may be useful for predicting treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“The current trial-and-error strategy for medication selection (Fochtman and Gelenberg, 2005) eventually leads to response for the majority of patients, but patients may have less than a 30% chance of recovery with an initial trial of an antidepressant medication (Trivedi et al., 2006).”
BackgroundAbstract reward and punishment representations in the human orbitofrontal cortex
O'Doherty, J., Kringelbach, M. L., Rolls, E. T., Hornak, J., & Andrews, C. (2001) · Nature Neuroscience · doi:10.1038/82959 · Cited by 2,003
Pezawas, L., Meyer-Lindenberg, A., Drabant, E. M., Verchinski, B. A., Munoz, K. E., Kolachana, B. S., Egan, M. F., Mattay, V. S., Hariri, A. R., & Weinberger, D. R. (2005) · Nature Neuroscience · doi:10.1038/nn1463 · Cited by 1,980
KRINGELBACH, M. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.03.006 · Cited by 1,977
Mayberg, H. S. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.193 · Cited by 1,166
Cingulate function in depression: a potential predictor of treatment response
Mayberg, H. S., Brannan, S. K., Mahurin, R. K., Jerabek, P. A., Brickman, J. S., Tekell, J. L., Silva, J. A., McGinnis, S., Glass, T. G., Martin, C. C., et al. (1997) · NeuroReport · doi:10.1097/00001756-199703030-00048 · Cited by 1,029
A Susceptibility Gene for Affective Disorders and the Response of the Human Amygdala
Hariri, A. R., Drabant, E. M., Munoz, K. E., Kolachana, B. S., Mattay, V. S., Egan, M. F., & Weinberger, D. R. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.146 · Cited by 815
Lane, R. D., Reiman, E. M., Axelrod, B., Yun, L.-S., Holmes, A., & Schwartz, G. E. (1998) · Journal of Cognitive Neuroscience · doi:10.1162/089892998562924 · Cited by 671
Pizzagalli, D., Pascual-Marqui, R. D., Nitschke, J. B., Oakes, T. R., Larson, C. L., Abercrombie, H. C., Schaefer, S. M., Koger, J. V., Benca, R. M., & Davidson, R. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.405 · Cited by 630 · cited 3×
“Theta current density studies have utilized Low-Resolution Brain Electromagnetic Tomography (LORETA), which is a widely used and well-validated QEEG source-localization algorithm (Seeck et al., 1998; Worrell et al., 2000; Oakes et al., 2004).”
BackgroundKong, J., Gollub, R. L., Rosman, I. S., Webb, J. M., Vangel, M. G., Kirsch, I., & Kaptchuk, T. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3556-05.2006 · Cited by 395
Szegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341 · cited 3×
“Conversely, the absence of early improvement during pharmacotherapy is associated with poor 8-week outcome (Nierenberg et al., 1995; Szegedi et al., 2009), although the lack of specificity of these changes limits the usefulness of this measure as a sole predictor (Leuchter et al., 2009b; Szegedi et…”
BackgroundAutoradiographic distribution of serotonin transporters and receptor subtypes in human brain.
Varnäs, K., Halldin, C., & Hall, H. (2004) · Human Brain Mapping · doi:10.1002/hbm.20035 · Cited by 332
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300341 · Cited by 252 · cited 1×
“…of pretreatment brain activity, numerous reports also have demonstrated a strong relationship between eventual response and symptom improvement in the first 2 weeks of treatment (Szegedi et al., 2003; Katz et al., 2004; Papakostas et al., 2007; Stassen et al., 2007; Szegedi et al., 2009).”
BackgroundFunctional coupling of simultaneous electrical and metabolic activity in the human brain
Oakes, T. R., Pizzagalli, D. A., Hendrick, A. M., Horras, K. A., Larson, C. L., Abercrombie, H. C., Schaefer, S. M., Koger, J. V., & Davidson, R. J. (2004) · Human Brain Mapping · doi:10.1002/hbm.20004 · Cited by 235
Warm pleasant feelings in the brain
Rolls, E. T., Grabenhorst, F., & Parris, B. A. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.03.005 · Cited by 227
Saxena, S., Brody, A. L., Ho, M. L., Zohrabi, N., Maidment, K. M., & Baxter, L. R. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.522 · Cited by 210
Meyer, J. H., Wilson, A. A., Sagrati, S., Miler, L., Rusjan, P., Bloomfield, P. M., Clark, M., Sacher, J., Voineskos, A. N., & Houle, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.156 · Cited by 182
Holmes, A. J., Bogdan, R., & Pizzagalli, D. A. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.223 · Cited by 57
Cited by
Pizzagalli, D. A., Webb, C. A., Dillon, D. G., Tenke, C. E., Kayser, J., Goer, F., Fava, M., McGrath, P., Weissman, M., Parsey, R., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0252 · Cited by 189
Salience Network Functional Connectivity Predicts Placebo Effects in Major Depression
Sikora, M., Heffernan, J., Avery, E. T., Mickey, B. J., Zubieta, J.-K., & Peciña, M. (2016) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2015.10.002 · Cited by 85
“Yet, the ability of these biomarkers to selectively distinguish drug-specific effects from other non-specific elements of the treatment response, such as the placebo effect, is still limited, with very few studies specifically addressing biomarkers of non-specific elements of antidepressant treatment response (14, 15).”
BackgroundResultJamieson, A. J., Harrison, B. J., Razi, A., & Davey, C. G. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01214-z · Cited by 41
Amygdala-frontal couplings characterizing SSRI and placebo response in social anxiety disorder
Faria, V., Åhs, F., Appel, L., Linnman, C., Bani, M., Bettica, P., Pich, E. M., Fredrikson, M., & Furmark, T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000352 · Cited by 37
“In addition, rACC has also been implicated in placebo responses across disorders (Faria et al., 2008; Bingel et al., 2011; Korb et al., 2011; Petrovic et al., 2002, 2005, 2010).”
Background
Metadata
- Authors
- Korb, A. S., Hunter, A. M., Cook, I. A., & Leuchter, A. F.
- Venue
- Psychiatry Research: Neuroimaging
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 192
- Issue
- 3
- Pages
- 188-194
- ISSN
- 0925-4927 (ISSN-L)
- OpenAlex
- W1971776908
- Cited by
- 59
- References
- 18
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.